Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 26, 2020 06:30 ET | Source: SpringWorks Therapeutics, Inc.

SpringWorks Therapeutics Appoints Julie Hambleton, M.D. to its Board of Directors

STAMFORD, Conn., May 26, 2020 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients...
May 12, 2020 07:30 ET | Source: SpringWorks Therapeutics, Inc.

SpringWorks Therapeutics Reports First Quarter 2020 Financial Results and Recent Business Highlights

- Announced Issuance of New U.S. Composition of Matter Patent to Polymorphic Form of Nirogacestat, Extending Patent Protection into 2039 - - Signed Clinical Collaboration with Allogene to Evaluate...
March 18, 2020 06:30 ET | Source: SpringWorks Therapeutics, Inc.

SpringWorks Therapeutics Announces Issuance of New U.S. Composition of Matter Patent to Polymorphic Form of Nirogacestat, Extending Patent Protection into 2039

STAMFORD, Conn., March 18, 2020 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX) announced today that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent...
March 12, 2020 16:30 ET | Source: SpringWorks Therapeutics, Inc.

SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Business Highlights

- Dosed the First Patients in the Phase 2b ReNeu Clinical Trial of Mirdametinib for Patients with Neurofibromatosis Type 1-Associated Plexiform Neurofibromas (NF1-PN) - - Signed Clinical...
February 27, 2020 07:14 ET | Source: SpringWorks Therapeutics, Inc.

MapKure, BeiGene and SpringWorks Announce Initiation of Phase 1 Clinical Trial of BGB-3245, a Selective Next-Generation B-RAF Inhibitor, in Adult Patients with Advanced or Refractory Solid Tumors

-- Phase 1 Study Initiated in Australia with IND Cleared to Expand Study to the U.S.-- -- Industry-Leading Scientific Advisory Board Formed to Support Advancement of BGB-3245 -- ...
February 18, 2020 06:30 ET | Source: SpringWorks Therapeutics, Inc.

SpringWorks Therapeutics to Present at the Cowen and Company 40th Annual Health Care Conference

STAMFORD, Conn., Feb. 18, 2020 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for...
January 06, 2020 06:30 ET | Source: SpringWorks Therapeutics, Inc.

SpringWorks Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference

STAMFORD, Conn., Jan. 06, 2020 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for...
December 09, 2019 10:00 ET | Source: SpringWorks Therapeutics, Inc.

Researchers Present Preclinical Data Showing Synergistic Activity of SpringWorks Therapeutics’ Gamma Secretase Inhibitor (Nirogacestat) with GlaxoSmithKline’s BCMA Antibody-Drug Conjugate (Belantamab Mafodotin) at the American Society of Hematology (ASH) Annual Meeting

STAMFORD, Conn., Dec. 09, 2019 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for...
November 12, 2019 08:00 ET | Source: SpringWorks Therapeutics, Inc.

SpringWorks Therapeutics Reports Third Quarter 2019 Financial Results and Recent Business Highlights

– Commenced Phase 2b ReNeu Clinical Trial for Patients with Neurofibromatosis Type 1-Associated Plexiform Neurofibromas (NF1-PN) – – Received Important Regulatory Designations for Nirogacestat...
October 24, 2019 06:30 ET | Source: SpringWorks Therapeutics, Inc.

SpringWorks Therapeutics Announces Initiation of Phase 2b ReNeu Clinical Trial of Mirdametinib in Children and Adults with Neurofibromatosis Type 1 (NF1)-Associated Plexiform Neurofibromas (NF1-PN)

STAMFORD, Conn., Oct. 24, 2019 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (NASDAQ: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for...